Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

Chi­nook’s read­out of its Phase III ALIGN tri­al of atrasen­tan, a po­ten­tial treat­ment for chron­ic kid­ney dis­eases, could be de­layed by about three months, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.